OPEN-LABEL STUDY INVESTIGATING EFFICACY, SAFETY AND PHARMACOKINETICS OF CONCIZUMAB PROPHYLAXIS IN CHILDREN BELOW 12 YEARS WITH HAEMOPHILIA A OR B WITH OR WITHOUT INHIBITORS
- Registry ID
- NN7415-4616
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NOVO NORDISK CANADA INC
- Start date
- 2024-09-13
- Last update
- 2021-12-21
Conditions
- HEMOPHILIA A
- HEMOPHILIA B
Related clinical trials
- A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
- AN OPEN-LABEL, PARALLEL, PHASE 3, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY AND
SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED 1 TO LESS THAN 12 YEARS
WITH HEMOPHILIA A OR B WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTORS VIII OR IX
- SYNOVIIIUS: PROSPECTIVE INTERVENTIONAL STUDY OF EFFECTIVENESS OF EFANESOCTOCOG ALFA PROPHYLAXIS ON SYNOVIAL HYPERTROPHY IN PATIENTS WITH HEMOPHILIA A
- A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9-BASED
COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B
- OPEN-LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF MIM8 IN PARTICIPANTS WITH HAEMOPHILIA A WITH OR WITHOUT INHIBITORS
- PHASE 3B, OPEN-LABEL, MULTICENTER, SINGLE-DOSE STUDY INVESTIGATING EFFICACY AND SAFETY OF CSL222 (ETRANACOGENE DEZAPARVOVEC) GENE THERAPY ADMINISTERED TO ADULT SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B WITH DETECTABLE PRETREATMENT AAV5 NEUTRALIZING ANTIBODIES
View on source registry